BiotechTube
Seragon Biosciences

Seragon Biosciences

San Diego, United States· Est.
seragon.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $105M

Overview

Seragon Biosciences is a private, pre-revenue biotech firm leveraging advanced AI and gene therapy platforms to target aging, metabolic disorders, and immunology. The company's core technologies include the GenomeScore™ AI platform for measuring aging and a hybrid gene therapy platform for efficient gene delivery. Operating in the high-growth longevity and gene therapy sectors, Seragon appears to be in a pre-clinical or discovery-stage, building its scientific foundation and seeking partnerships to advance its research programs.

Aging/LongevityMetabolic DisordersGenetic DisordersImmunology

Technology Platform

GenomeScore™ AI platform (epigenetics & transcriptomics for aging biomarkers); Hybrid Gene Therapy Platform (controllable multiplex viral vectors); AI Vaccine Design platform.

Funding History

2
Total raised:$105M
Series B$75M
Series A$30M

Opportunities

Seragon operates in massive, high-growth markets including longevity, gene therapy, and AI-driven drug discovery.
Its multi-platform approach, combining AI with advanced delivery systems, could create synergistic advantages in developing personalized therapies and biomarkers.
The company's stated interest in both human and animal health provides potential for dual-market applications and de-risking.

Risk Factors

The company is at an extremely early, pre-clinical stage with unproven technology platforms, facing high scientific and technical risk.
A lack of visible funding details and leadership information creates significant uncertainty regarding financial runway and execution capability.
It also faces intense competition in each of its focus areas from well-capitalized entities.

Competitive Landscape

Seragon competes in crowded and sophisticated fields. In longevity, it faces competitors like Unity Biotechnology, Calico (Alphabet), and numerous biotech startups. In gene therapy, it competes with established platforms from companies like Spark Therapeutics (Roche) and newer vector engineering firms. Its AI focus pits it against a growing ecosystem of AI-native drug discovery companies such as Recursion, Exscientia, and Insilico Medicine.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →